Compare Stocks: BFRI, TENX, LONA, and SPRO

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BFRI Biofrontera	$1.32 +6.5%	$1.31	$0.55 ▼ $1.66	$19.60M	0.83	796,121 shs	375,462 shs
LONA Athira Pharma	$6.79 -2.3%	$7.63	$3.60 ▼ $14.21	$63.78M	2.05	40,282 shs	52,315 shs
SPRO Spero Therapeutics	$1.13 +0.9%	$1.26	$1.08 ▼ $3.08	$65.81M	1.49	327,356 shs	501,370 shs
TENX Tenax Therapeutics	$1.90 +2.2%	$7.06	$1.31 ▼ $19.40	$71.11M	0.83	5.64 million shs	7.06 million shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BFRI Biofrontera	0.00%	-14.84%	-10.81%	+33.74%	+55.29%
LONA Athira Pharma	0.00%	-1.88%	-11.82%	-16.99%	+678,999,900.00%
SPRO Spero Therapeutics	0.00%	0.00%	-6.61%	-50.44%	-40.53%
TENX Tenax Therapeutics	0.00%	+2.15%	+6.74%	-84.17%	-69.60%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BFRI Biofrontera	$1.32 +6.5%	$1.31	$0.55 ▼ $1.66	$19.60M	0.83	796,121 shs	375,462 shs
LONA Athira Pharma	$6.79 -2.3%	$7.63	$3.60 ▼ $14.21	$63.78M	2.05	40,282 shs	52,315 shs
SPRO Spero Therapeutics	$1.13 +0.9%	$1.26	$1.08 ▼ $3.08	$65.81M	1.49	327,356 shs	501,370 shs
TENX Tenax Therapeutics	$1.90 +2.2%	$7.06	$1.31 ▼ $19.40	$71.11M	0.83	5.64 million shs	7.06 million shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BFRI Biofrontera	0.00%	-14.84%	-10.81%	+33.74%	+55.29%
LONA Athira Pharma	0.00%	-1.88%	-11.82%	-16.99%	+678,999,900.00%
SPRO Spero Therapeutics	0.00%	0.00%	-6.61%	-50.44%	-40.53%
TENX Tenax Therapeutics	0.00%	+2.15%	+6.74%	-84.17%	-69.60%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BFRI Biofrontera	2.00	Hold	N/A	N/A
LONA Athira Pharma	2.50	Moderate Buy	$17.33	155.28% Upside
SPRO Spero Therapeutics	2.25	Hold	$6.00	430.97% Upside
TENX Tenax Therapeutics	2.40	Hold	$14.00	636.84% Upside

Current Analyst Ratings Breakdown

Latest BFRI, TENX, LONA, and SPRO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/14/2026	TENX Tenax Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
9/14/2026	SPRO Spero Therapeutics	Compass Point Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Neutral
9/14/2026	SPRO Spero Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold
9/14/2026	SPRO Spero Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$5.00 ➝ $6.00
9/10/2026	TENX Tenax Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
8/31/2026	TENX Tenax Therapeutics	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Neutral
8/31/2026	TENX Tenax Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Neutral
8/28/2026	TENX Tenax Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/19/2026	LONA Athira Pharma	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$16.00 ➝ $15.00
8/17/2026	LONA Athira Pharma	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Market Outperform	$18.00 ➝ $17.00
8/12/2026	SPRO Spero Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D-) ➝ Hold (C-)

(Data available from 9/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BFRI Biofrontera	$41.71M	0.47	N/A	N/A	$0.90 per share	1.47
LONA Athira Pharma	N/A	N/A	N/A	N/A	$2.98 per share	N/A
SPRO Spero Therapeutics	$66.80M	0.99	$0.15 per share	7.43	$1.05 per share	1.08
TENX Tenax Therapeutics	N/A	N/A	N/A	N/A	$10.42 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BFRI Biofrontera	-$10.54M	-$0.45	N/A	N/A	N/A	-13.78%	-145.81%	-31.30%	11/11/2026 (Estimated)
LONA Athira Pharma	-$105.61M	-$4.21	N/A	N/A	N/A	N/A	-411.58%	-225.73%	N/A
SPRO Spero Therapeutics	$8.57M	$0.11	10.27	N/A	N/A	24.90%	16.17%	12.57%	11/12/2026 (Estimated)
TENX Tenax Therapeutics	-$52.60M	-$1.48	N/A	N/A	N/A	N/A	-61.54%	-57.42%	11/11/2026 (Estimated)

Latest BFRI, TENX, LONA, and SPRO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q2 2026	LONA Athira Pharma	-$0.60	-$0.80	-$0.20	-$0.80	N/A	N/A
8/13/2026	Q2 2026	BFRI Biofrontera	-$0.1050	-$0.05	+$0.0550	-$0.05	$9.50 million	$12.00 million
8/12/2026	Q2 2026	SPRO Spero Therapeutics	-$0.17	-$0.16	+$0.01	-$0.16	N/A	N/A
7/31/2026	Q2 2026	TENX Tenax Therapeutics	-$0.3813	-$0.35	+$0.0313	-$0.35	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BFRI Biofrontera	N/A	N/A	N/A	N/A	N/A
LONA Athira Pharma	N/A	N/A	N/A	N/A	N/A
SPRO Spero Therapeutics	N/A	N/A	N/A	N/A	N/A
TENX Tenax Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BFRI Biofrontera	0.78	1.18	1.08
LONA Athira Pharma	N/A	7.01	7.01
SPRO Spero Therapeutics	N/A	6.12	6.12
TENX Tenax Therapeutics	N/A	15.07	15.07

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BFRI Biofrontera	10.08%
LONA Athira Pharma	57.12%
SPRO Spero Therapeutics	25.60%
TENX Tenax Therapeutics	1.67%

Insider Ownership

Company	Insider Ownership
BFRI Biofrontera	8.10%
LONA Athira Pharma	25.73%
SPRO Spero Therapeutics	2.90%
TENX Tenax Therapeutics	10.81%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BFRI Biofrontera	94	14.85 million	13.65 million	No Data
LONA Athira Pharma	19	9.39 million	6.98 million	No Data
SPRO Spero Therapeutics	150	58.24 million	56.55 million	Optionable
TENX Tenax Therapeutics	16	37.42 million	33.38 million	Not Optionable

BFRI, TENX, LONA, and SPRO Headlines

Recent News About These Companies

Tenax Therapeutics (NASDAQ:TENX) Director Declan Doogan Purchases 53,000 Shares of Stock

September 18 at 7:22 AM | insidertrades.com

Declan Doogan Purchases 53,000 Shares of Tenax Therapeutics (NASDAQ:TENX) Stock

September 17 at 11:07 PM | marketbeat.com

Tenax Therapeutics, Inc. (NASDAQ:TENX) Short Interest Update

September 16, 2026 | marketbeat.com

Piper Sandler Remains a Buy on Tenax Therapeutics (TENX)

September 16, 2026 | theglobeandmail.com

Tenax Therapeutics (NASDAQ:TENX) CEO Acquires $11,280.00 in Stock

September 16, 2026 | insidertrades.com

Tenax Therapeutics (NASDAQ:TENX) CEO Christopher Thomas Giordano Buys 6,000 Shares

September 15, 2026 | marketbeat.com

Adar1 Capital Management, Llc Buys 900,000 Shares of Tenax Therapeutics (NASDAQ:TENX) Stock

September 10, 2026 | americanbankingnews.com

Tenax Therapeutics (NASDAQ:TENX) Major Shareholder Buys $1,602,000.00 in Stock

September 9, 2026 | insidertrades.com

Tenax Therapeutics, Inc. (NASDAQ:TENX) Receives Consensus Recommendation of "Hold" from Brokerages

September 9, 2026 | americanbankingnews.com

Tenax Therapeutics (NASDAQ:TENX) Major Shareholder Adar1 Capital Management, Llc Purchases 900,000 Shares of Stock

September 8, 2026 | marketbeat.com

Tenax (TENX) Found a 26.3-Meter Benefit in a Prespecified Subgroup After LEVEL Missed Its Primary Endpoint. Is Another Phase 3 Trial Viable?

September 4, 2026 | insidermonkey.com

Tenax Therapeutics, Inc. (NASDAQ:TENX) Given Consensus Rating of "Hold" by Brokerages

September 4, 2026 | marketbeat.com

Insider Buying: Tenax Therapeutics (NASDAQ:TENX) Major Shareholder Purchases $322,304.40 in Stock

September 3, 2026 | insidertrades.com

Braidwell LP Acquires New Holdings in Tenax Therapeutics, Inc. $TENX

September 3, 2026 | marketbeat.com

Tenax Therapeutics (NASDAQ:TENX) Major Shareholder Purchases 179,058 Shares of Stock

September 2, 2026 | marketbeat.com

Adar1 Capital Management, Llc Purchases 187,704 Shares of Tenax Therapeutics (NASDAQ:TENX) Stock

September 2, 2026 | marketbeat.com

Tenax Therapeutics (NASDAQ:TENX) Major Shareholder Adar1 Capital Management, Llc Buys 403,571 Shares

September 2, 2026 | marketbeat.com

Guggenheim downgrades Tenax Therapeutics (TENX)

September 2, 2026 | msn.com

Tenax Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference

September 1, 2026 | globenewswire.com

Tenax's Phase 3 Study For TNX-103 Fails To Meet Primary Endpoint; Shows Success In Other Measures

August 30, 2026 | rttnews.com

Tenax finds benefit in sicker patient subgroup after Phase 3 trial miss

August 30, 2026 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BFRI, TENX, LONA, and SPRO Company Descriptions

Biofrontera NASDAQ:BFRI

$1.32 +0.08 (+6.45%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$1.31 -0.01 (-0.98%)

As of 09/18/2026 07:58 PM Eastern

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.

Athira Pharma NASDAQ:LONA

$6.79 -0.16 (-2.30%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$6.67 -0.12 (-1.83%)

As of 09/18/2026 04:17 PM Eastern

Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies. The company's product pipeline includes ATH-1020, an orally available brain-penetrant small molecule designed to enhance the HGF/MET system that is in Phase 1 clinical trials to treat neuropathic pain and neurodegenerative diseases; and ATH-1105, an oral small molecule drug candidate, which is a preclinical model for the treatment of Amyotrophic Lateral Sclerosis. In addition, it has a license agreement with Washington State University to offer for sale products covered by certain licensed patents, including dihexa, the chemical compound into which fosgonimeton metabolizes following administration; and collaboration and grant agreement with National Institutes of Health Grant to support ACT-AD Phase 2 clinical trial for fosgonimeton. The company was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. Athira Pharma, Inc. was incorporated in 2011 and is headquartered in Bothell, Washington.

Spero Therapeutics NASDAQ:SPRO

$1.13 +0.01 (+0.89%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$1.12 0.00 (-0.44%)

As of 09/18/2026 07:30 PM Eastern

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; and Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. Spero Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Tenax Therapeutics NASDAQ:TENX

$1.90 +0.04 (+2.15%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$1.91 +0.01 (+0.74%)

As of 09/18/2026 07:59 PM Eastern

Tenax Therapeutics, Inc. develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is based in Chapel Hill, North Carolina.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BFRI, TENX, LONA, and SPRO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BFRI, TENX, LONA, and SPRO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BFRI, TENX, LONA, and SPRO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

BFRI, TENX, LONA, and SPRO Company Descriptions

Biofrontera NASDAQ:BFRI

Athira Pharma NASDAQ:LONA

Spero Therapeutics NASDAQ:SPRO

Tenax Therapeutics NASDAQ:TENX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BFRI, TENX, LONA, and SPRO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BFRI, TENX, LONA, and SPRO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BFRI, TENX, LONA, and SPRO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

BFRI, TENX, LONA, and SPRO Company Descriptions

Biofrontera NASDAQ:BFRI

Athira Pharma NASDAQ:LONA

Spero Therapeutics NASDAQ:SPRO

Tenax Therapeutics NASDAQ:TENX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools